Ebvallo, which Pierre Fabre Pharmaceuticals and Atara Biotherapeutics are proposing to treat a posttransplant complication, ...
AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the release of a new installment of its CEO ...
Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended ...
(PFP), has resubmitted the tabelecleucel Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). ...
Repeat-dose GLP toxicology study showed no ERNA-101-related adverse findings across all dose levels tested, including no ...
Novel systemic immune data demonstrated T-cell activation following local administration of aglatimagene. Together with ...
Candidate selected by GSK utilizes Wave’s best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three ...
IM-1340 incorporates Immunome's proprietary HC74 topoisomerase I inhibitor payload and targets a transport receptor expressed ...
Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company ...
Addition of NVIDIA Nemotron models and Hermes runtime expands customer choice across both AI models and agent software.
Results mark the first positive Phase 2 data for an anti-TL1A monoclonal antibody in dermatology. Tulisokibart was designed ...
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced research advancing understanding of Prader-Willi syndrome and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results